Pfizer and Crown Bioscience have entered into a collaboration to research and develop novel therapeutics for Asian cancers. Specific treatments for Asian cancers represent an important unmet medical need as well as a significant market opportunity, according to a joint statement. Crown will receive an upfront payment and research funding, as well as milestone payments based on the achievement of preclinical and clinical goals, but financial terms were not disclosed. The companies will work to...